Julien Mazières

25PUBLICATIONS
232CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Query processing and optimisationPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Mar 03, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Thomas Pierre Walter, Julien Mazieres, Josiane Otto

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Jul 31, 2025
Federated Analysis With Differential Privacy in Oncology Research: Longitudinal Observational Study Across Hospital Data Warehouses.

Théo Ryffel, Perrine Créquit, Maëlle Baillet

|Mar 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.

Jean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah

|Jun 27, 2024
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.

Sarah Figarol, Célia Delahaye, Rémi Gence

Pageof 5

Frequent Collaborators

4 joint publications

Laurent Greillier

4 joint publications

Alexis Cortot

4 joint publications

Denis Moro-Sibilot

3 joint publications

Gérard Zalcman